Farnir Florent, Chaldoupi Sevasti-Maria, Hermans Ben J M, Farnir Frédéric, Habibi Zarina, Jerltorp Kezia, Verhaert Dominique, Schotten Ulrich, Maesen Bart, Vernooy Kevin, Luermans Justin, Linz Dominik
Department of Cardiology, Cardiovascular Research Institute Maastricht (CARIM), Maastricht University Medical Centre, Maastricht, The Netherlands.
Department of Biostatistics and Bioinformatics, FARAH, Faculty of Veterinary Medicine, University of Liege, Liège, Belgium.
Heart Rhythm. 2025 Aug;22(8):1957-1968. doi: 10.1016/j.hrthm.2025.01.015. Epub 2025 Jan 17.
Focal pulsed field ablation (F-PFA) integrated in electroanatomic mapping systems allows tailored lesion sets in patients with atrial fibrillation (AF).
We aimed to determine feasibility, safety, and 6-month outcome of F-PFA for a tailored substrate-based catheter ablation approach in patients with AF and advanced atrial substrate.
Consecutive patients with AF and advanced atrial substrate treated by an F-PFA system (CardioFocus) through contact force-sensing catheters integrated in electroanatomic mapping systems were prospectively enrolled. The tailored substrate-based catheter ablation approach included isolation of all pulmonary veins with wide area circumferential ablation, posterior wall isolation, mitral anterior line, and cavotricuspid isthmus ablation, according to substrate. At 6 months, feasibility, arrhythmia recurrence, and safety were evaluated.
In 83 patients (33% female; indexed left atrial volume, 44 ± 15 mL/m; 80% persistent AF or atrial flutter [AFl]; 57% redo procedures), successful de novo pulmonary vein isolation was performed in 36 patients and pulmonary vein reisolation in 30 patients. Mitral anterior line was performed in 19 patients with atypical AFl or anterior low-voltage areas; posterior wall isolation was performed in 38 patients with low-voltage areas or evoked delayed electrograms during premature atrial extrastimuli; and cavotricuspid isthmus ablation was performed in 24 patients with typical AFl. Median procedural and fluoroscopy times were 115 and 7 minutes, respectively. No complications occurred. At 6 months, arrhythmia recurred in 30 of 83 patients (21 AF; 9 atypical AFl).
Tailored substrate-based F-PFA in patients with AF and advanced atrial substrate is safe and effective. Acute procedural success was 100% with 64% freedom from arrhythmias after 6 months.
集成在电解剖标测系统中的局灶脉冲场消融(F-PFA)可对心房颤动(AF)患者进行定制化的消融灶设置。
我们旨在确定F-PFA用于AF和晚期心房基质患者基于基质定制的导管消融方法的可行性、安全性及6个月的结局。
前瞻性纳入通过集成在电解剖标测系统中的接触力感知导管,采用F-PFA系统(CardioFocus)治疗的AF和晚期心房基质的连续患者。基于基质定制的导管消融方法包括根据基质情况,通过大面积环周消融隔离所有肺静脉、后壁隔离、二尖瓣前壁线消融以及腔静脉-三尖瓣峡部消融。在6个月时,评估可行性、心律失常复发情况及安全性。
83例患者(女性占33%;左心房指数容积为44±15 mL/m;80%为持续性AF或心房扑动[AFl];57%为再次手术)中,36例患者成功进行了初次肺静脉隔离,30例患者进行了肺静脉再次隔离。19例非典型AFl或前壁低电压区患者进行了二尖瓣前壁线消融;38例低电压区或心房早搏刺激时诱发延迟电位的患者进行了后壁隔离;24例典型AFl患者进行了腔静脉-三尖瓣峡部消融。手术时间和透视时间中位数分别为115分钟和7分钟。未发生并发症。6个月时,83例患者中有30例(21例AF;9例非典型AFl)心律失常复发。
对于AF和晚期心房基质患者,基于基质定制的F-PFA安全有效。急性手术成功率为100%,6个月后64%的患者无心律失常发作。